Kanuma (Sebelipase Alfa)

Sebelipase Alfa is a recombinant form of human lysosomal acid lipase. When administered intravenously, it enters cells and localises to lysosomes, where it hydrolyses cholesteryl esters and triglycerides. This restores normal lipid catabolism, decreasing storage material in the liver, spleen and other tissues.

The dose of Kanuma is individualized by the prescribing clinician based on the patient’s body weight, disease severity and clinical response. No fixed regimen is provided here; the healthcare professional will calculate the appropriate amount and infusion schedule for each patient.

Safety data for Kanuma in pregnancy and lactation are limited. The product is classified as having an unknown pregnancy category, and it should only be used if the potential benefit justifies any potential risk to the fetus or infant. Breastfeeding decisions should be made in consultation with a physician.

To order Kanuma, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After verification of trade or institutional credentials, the sales team will provide pricing, availability, cold‑chain shipping details and any necessary import documentation.

Kanuma is the only approved enzyme replacement therapy that directly replaces deficient lysosomal acid lipase. Alternative approaches are limited to supportive care such as lipid‑lowering agents and dietary management, which do not address the underlying enzymatic defect. Therefore, Kanuma offers a disease‑modifying option not available with other drug classes.

Kanuma must be stored refrigerated between 2 °C and 8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. If temperature excursions occur, discard the product according to the supplier’s guidelines.

Kanuma is supplied as a sterile solution for injection and is given by intravenous infusion. The infusion is typically performed in a clinical setting under medical supervision, with the rate and duration determined by the prescribing physician based on patient tolerance and response.

The most serious adverse events include severe hypersensitivity reactions such as anaphylaxis, significant elevations in liver enzymes indicating hepatic injury, and hematologic abnormalities like thrombocytopenia. Patients should be monitored closely during and after infusion for any signs of these reactions.

Kanuma is contraindicated in patients with known hypersensitivity to sebelipase alfa or any component of the formulation. Caution is also advised for individuals with uncontrolled cardiac disease, severe hepatic impairment, or those receiving live vaccines concurrently.